脊得舒丸联合督灸治疗强直性脊柱炎46例

Treating 46 cases of ankylosing spondylitis with the Jideshu Wan plus Du-moxibustion therapy

目的:观察脊得舒丸联合督灸治疗强直性脊柱炎的临床疗效。方法:选取2014年1月-2017年1月诊治于河南省中医院的46例强直性脊柱炎患者为观察对象,利用计算机随机数发生器将上述患者随机分为治疗组和对照组,每组23例,对照组予常规西药治疗,治疗组在对照组基础上加用脊得舒丸联合督灸疗法。分别对两组治疗前后治疗有效性、实验室指标、功能性指标及患者疼痛情况进行对比分析。结果:治疗组总有效率为86.96%(20/23),对照组总有效率为56.52%(13/23),治疗组疗效明显优于对照组,且差异具有统计学意义(P <0.05);两组治疗前BASDAI、BASFI、VAS评分及其他相关指标相比,差异均无统计学意义(P> 0.05);治疗后相较于对照组,治疗组BASDAI、BASFI、VAS评分及其他相关指标均有所降低,差异有统计学意义(P <0.05)。结论:脊得舒丸联合督灸治疗强直性脊柱炎临床疗效确切,具有实用性,值的临床推广使用。

Objective： To observe the clinical efcacy of the Jideshu Wan （ 脊得舒丸 ） plus Du-moxibustion therapy （ 督灸 ） on ankylosing spondylitis. Methods： From Jan. 2014 to Jan. 2017, 46 patients with ankylosing spondylitis in Henan Province Hospital of TCM were divided into the treatment group and the control group with the help of computer random number generator, 23 patients in each group. The control group was treated with conventional western medicine. The treatment group was treated with the Jideshu Wan plus Du-moxibustion therapy. The clinical efcacy, laboratory index, functional index and patients’ pain were compared and analyzed before and after treatment in two groups. Results： The total efciency in the treatment group was 86.96% （20/23）, and was 56.52% （13/23） in the control group. The curative efect in the treatment group was obviously better, with a statistically signifcant diference （P〈0.05）. There was no signifcant diference in BASDAI, BASFI, VAS scores and other related indicators between two groups before treatment （P〉0.05）. After treatment, compared with the control group, the BASDAI, BASF, VAS scores and other related indexes in the treatment group were lower, with a statistically signifcant diference （P〈0.05）. Conclusion： The Jideshu Wan plus Du-moxibustion therapy on ankylosing spondylitis is accurate and practical, and is worthy of clinical consideration.